Regarding this excellent interview on Al Jazeera of Dr. NP

New Post Public Reply Private Reply Replies (3) Message Board
blafarm
814
Regarding this excellent interview on Al Jazeera of Dr. NP which was posted just yesterday:

Video Link: https://www.youtube.com/watch?v=iBHRTf9Q7eA

There are a couple of "big ticket" topics that I have not heard anyone raise:

Video Link = https://youtu.be/iBHRTf9Q7eA?t=156
Quote:
"We are now close to asking the FDA to approve the drug for compassionate use for everybody who is in severe condition because our mechanism of action which will be publishing a paper hopefully by the end of this week or so"
My Comments:

1. Other than CytoDyn's (assumed) failed attempt to gain FDA approval based upon the relatively small, non-control, EIND program, I don't remember any previous statement by Dr. NP regarding asking the FDA for approval of the drug for compassionate use.

Does anyone else remember this?

Is this a preview of what might be discussed on Monday?



2. At the very end of the Friday, April 17 conference call, while discussing his research paper, Dr. BP indicated that all of the data would finally be available in one week (that was yesterday), and that the paper would be submitted in two weeks (next Friday), and that it would not be published for 4-6 weeks (between May 8 and May 21). And, I noted in a post around that time that the release of paper would coincide nicely with the read-out of 2-week preliminary results. In this Al Jazeera interview, Dr. NP is stating: "... we will be publishing a paper hopefully by the end of this week."

My Comments:

Am I assigning too much significance to this remark?

Does anyone think the paper will be publicly circulated prior to being officially published between May 8 and May 21, according to Dr. BP?


3. Video Link: https://youtu.be/iBHRTf9Q7eA?t=188
Quote:
Correspondent: “So if the FDA gives you final approval would that also apply to other countries would it be good enough for the European Union or other countries to go ahead and start using the medication?

Dr. NP: “So each country has their own rules and regulation. United Kingdom has asked us already for the product to be involved in this test that we have they have indicated that the European Food and Drug Administration is agreeing to allow this product to be used in any clinical trial as long as the FDA in United States agrees to allow the clinical trials to go forward and have a green light. We have green light not for Phase 2 but also for one Phase 3 the final pivotal trial we believe and the other countries also always they follow the guidelines of FDA United States and the European Food and Drug Administration. So if both of these are aligned then the rest of the world would also immediately would allow us to be used for this special problem."
My Comments:

I have no idea what to make of Dr. NP's response. Can anyone interpret this for me -- in a clear and concise manner that allows me to understand/predict if we may hear that the UK has approved emergency use of leronlimab, as was discussed in that same April 17th conference call?

4. Video Link: https://youtu.be/iBHRTf9Q7eA?t=326
Quote:
In United States we have Bill Gates Foundation, NIH National Institute of Health Foundation reserve fundings we have
Quote:
amfAR that has funding, Barda has funding -- so all these funds that could be used to disperse this product without any cost to the third-world countries is going to be at work immediately. I have been approached already by a couple those institutions and they are saying that your science look very strong, your results look strong, if we if it happens that you get approval which could happen in the next perhaps six to eight weeks even, if those best-case scenario happen can we be involved to immediately have this product available for third world country? And we said absolutely yes. They asked us for the cost of the product. The cost is very minimum it's not very large and it's we are able to cover the whole world. We have our manufacturing at Samsung biologic in South Korea said where they could produce tremendous amount of product. And we have manufacturing United States ready to go. Everything set we need the FDA approval and we needed to have some proof of concept. Things are going very well with the patients who have received this product in Emergency IMD and reported it. But the trial is double-blinded we don't know the results for another two or three weeks and then we will know what path we have to take.
My Comments:

I like that Dr. NP has stated he has "been approached already by a couple those institutions". I think we had all hoped/assumed that had taken place (due to the strength of the drug's efficacy) -- but now we have clear evidence.

I also like his comment "The cost is very minimum it's not very large and it's we are able to cover the whole world." I like that he is going on record as being able to scale production and distribution (my words) to the entire world.

Regarding pricing, we all know the cost issue is a double edged sword. In the context of a pandemic , the company's reputation would be permanently damaged if CytoDyn pulled a "Martin Shkreli" and price-gouged the entire world.

This is an incredibly important inflection point for the company, and it must exit this pandemic looking like the hero that saved the world -- and that saved the world like the other big pharma companies promised to do -- effectively for free.

However, when this is over, and CytoDyn moves forward to monetize leronlimab for other indications, I anticipate some blow-back regarding pricing. I can see the headlines: "Company that saved the world is now overcharging for their drug."

I also anticipate an overhang in inventory, with potentially millions of unused vials sitting all over the planet -- at the point that a vaccine is available.

Whether or not those vials will have expired (as suggested by another board member), whether or not an expired vial still has any effectiveness, and whether or not doctors around the world will inject their patients suffering from other diseases with those vials -- all remains to be seen.

However, we have to assume that by the time a vaccine is ready, and those vials are no longer necessary, we will have had FDA approval for Combo HIV, and maybe even a label extension for Mono HIV. And who knows how much progress will have been made, or how many BTD's we might have acquired, for other cancer and immuno indications.

In other words, the temptation to use those vials, in both 1st world and especially in 3rd world countries, might be very strong. And that glut of inventory will certainly have an impact on demand and revenue.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

OFRM Faces Legal Heat Over Toddler Snack Recall

Updated Category News Views 122

OFRM Under the Microscope: Who Saw This Coming? Smack dab in the middle of navigating everyday market volatility, here's Once Upon A Farm (NYSE: OFRM) taking the spotlight—but for all the wrong reasons. The company got slapped with a stark FDA warning. Their Tractor Wheels toddler snacks allegedly pose a choking risk— think 'dry, sticky mass' refusing to budge with...

Continue Reading
Painter's Accessory Aims to Revolutionize Convenience

Updated Category News Views 64

Crafty New Invention Targets Painters' Ease Ever find yourself tangled in paintbrushes and rollers while trying to get that perfect coat on the wall? Well, a painter from Bracebridge, Ontario, has had it with the struggle and is looking to stir the pot with their latest invention, the NU LIFE LINER. It's sleek, it's practical, and it's aimed at flipping the painting game...

Continue Reading
A&G Management's Bold New Era with WPM Partnership

Updated Category News Views 122

Shaking Up Baltimore's Real Estate Scene Swapping up management partners can be a dicey game, but A&G Management seems to be pulling it off without a hitch. As of January 4, 2027, WPM Real Estate Management will take over the reins for more than 3,000 apartment homes scattered across Anne Arundel, Howard, and Baltimore counties. A new set of hands is stepping in for...

Continue Reading
Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 127

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading
HLTH USA 2026 Spotlights AI and Health Innovation

Updated Category News Views 113

The Pulse of Innovation at HLTH USA 2026 Diving headfirst into the heart of healthcare innovation, HLTH USA 2026 kicked off with gusto in Las Vegas. Discussions are swirling around AI advancements and the next generation of payer-provider collaboration. Who knew healthcare could be this thrilling? The event is already shaping up to be a powerhouse of change, buzzing with...

Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 119

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
Sovereign Crown Vault's Auction Draws Numismatic Collectors

Updated Category News Views 82

A Legendary Auction with Three Generations of Passion Coins, eh? They might just be small metallic disks to the untrained eye, but these suckers tell stories that stretch beyond any bank ledger. Sovereign Crown Vault LLC knows this, and they’re gearing up for quite the show on November 22, 2026. Their Holiday Season Kickoff Spectacular is about to lure in collectors...

Continue Reading
Ainstein Expands Kansas Operations Amid Sensor Demand Surge

Updated Category News Views 97

Ainstein's Expansion Conquers New Heights in Radar Tech Ainstein just cranked open a whole new chapter right in the heart of Kansas. And believe me, it's not your average ribbon-cutting story. This shiny new facility in Lenexa is locked and loaded to roll out 44,000 radar sensors a year. It's part of a no-nonsense plan to keep up with soaring demand for their tech across...

Continue Reading
Charlotte's Top-Tier Home Sales Surge: A $15M Milestone

Updated Category News Views 114

Charlotte's Luxury Market: A Rapid Ascent Folks, buckle up, because the luxury home market in Charlotte isn't just on the rise—it's practically sky-high. Back in 2016, the idea of splashing out over $5 million on a house was almost unheard of in this neck of the woods. Only one brave soul did it at the time. Fast forward to this past year, and things are looking starkly...

Continue Reading
191 Schools Honored for Academic Growth Success

Updated Category News Views 116

Celebrating Educational Progress Nationwide In a world where numbers fly off the stock tickers and translate into dollar signs in some corner office, it's refreshingly humbling to find real gains being celebrated in the educational sector. Curriculum Associates has tipped their hat to 191 schools that have done something remarkable: they've pushed students to stretch...

Continue Reading

Top 5 Most Recently Viewed Articles

Passage Bio's Upcoming Presentation at Genetic Medicines Conference

Updated Category News Views 45

Passage Bio's Work in Genetic Medicine Advancements Passage Bio, Inc. (NASDAQ: PASG), based in Philadelphia, is making notable progress in the area of genetic therapies, with a mission to offer hope to patients battling neurodegenerative diseases. Will Chou, M.D., the company's president and CEO, is set to present at the esteemed Chardan's 8th Annual Genetic Medicines...

Continue Reading
Experience the Sweet Taste of Christmas with Purdys Chocolatier

Updated Category News Views 248

Discover the Magic of the Holiday Season with Purdys Purdys Chocolatier, a beloved Canadian chocolatier since 1907, is getting ready to sprinkle some festive cheer this holiday season. With a delightful range of holiday chocolates, they aim to make every home a little sweeter. Purdys Chocolatier’s Christmas Collection is sure to have something special for everyone on...

Continue Reading
Warmy.io Launches Adeline AI to Enhance Email Deliverability

Updated Category News Views 253

Enhancing Email Deliverability with Adeline AI Warmy.io, a cutting-edge platform focused on improving email deliverability, has made waves in the digital marketing realm with its innovative solution, Adeline AI. This advanced system is designed to tackle one of the most pressing challenges in email marketing—ensuring that emails reach the primary inbox instead of...

Continue Reading
Unleashing the Potential of Community-Based Trials for Health

Updated Category News Views 87

Understanding Community-Based Trials In a unique approach to enhancing clinical research, community-based trials are making significant strides by prioritizing patient accessibility. This webinar is designed to provide an enlightening perspective on how these trials are tailored to meet the needs of local populations. The focus will be on how community-site networks and...

Continue Reading
Dovid Oved Retreat Center's Generous Support for Firefighters

Updated Category News Views 203

A Community's Commitment to Emergency Responders The Dovid Oved Retreat Center recently hosted a heartfelt barbecue to show appreciation for over 110 firefighters battling the devastating Line Fire. This wildfire has consumed large areas of land and posed a significant threat not only to the retreat center but also to the local community. Offering Essential Resources...

Continue Reading